Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Chow WA, et al. Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. doi: 10.1007/s00280-004-0803-4. Epub 2004 Jun 2. Cancer Chemother Pharmacol. 2004. PMID: 15173955 Clinical Trial.
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Raschko J, Shibata S, Tetef M, Molina A, Berenson RJ, Forman SJ, Doroshow JH. Somlo G, et al. Blood. 1997 Mar 1;89(5):1521-8. Blood. 1997. PMID: 9057632 Free article.
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.
Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E, Planás I, Kashyap A, Spielberger R, Fung H, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Blume KG, Niland J, Forman SJ. Nademanee A, et al. Blood. 1997 Nov 15;90(10):3844-52. Blood. 1997. PMID: 9354650 Free article. Clinical Trial.
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ Jr, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Morgan RJ Jr, et al. Cancer Res. 1998 Jul 1;58(13):2793-800. Cancer Res. 1998. PMID: 9661893 Clinical Trial.
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Somlo G, et al. Blood. 1999 May 1;93(9):2798-806. Blood. 1999. PMID: 10216073 Free article. Clinical Trial.
86 results